title: [Prognostic value of (18)F-FDG PET/CT after first-line treatment in patients with diffuse large B cell lymphoma].
abstract: OBJECTIVE
  To evaluate the value of (18)F-FDG PET/CT in detecting residual disease and predicting relapse following first-line treatment in patients with diffuse large B cell lymphoma (DLBCL).
  
  
  METHODS
  The clinical data of 39 patients with DLBCL, who underwent PET/CT scan after first-line treatment, were analyzed retrospectively. Kaplan-Meier method was used to analyze the survival of patients.
  
  
  RESULTS
  PET/CT findings were interpreted as negative, mild metabolism and positive. Seventeen patients' PET/CT findings were judged as negative, none of them relapsed with a median follow-up of 24.1 months, 13 were judged as mild metabolism, 2 of them relapsed with a median follow-up of 17.1 months. Of the rest 9 findings were judged as positive with a median follow-up of 16.3 months, 4 patients were considered as disease progression according to clinical manifestations and other radiographic results, 2 patients relapsed at the time points of 13.5 and 6.8 months after PET/CT scan respectively, the other 3 patients were diagnosed as negative by biopsy, none of them relapsed at the time points of 5.9, 9.6 and 20.0 months after PET/CT scan respectively. One-year progression-free-survival (PFS) for negative, mild metabolism and positive groups was 100%, 83% and 56%, respectively. Two-year PFS was 100%, 83% and 42%, respectively. Overall survival (OS) at 1 year for negative, mild metabolism and positive groups was 100%, 100% and 89%, respectively. Two-year OS was 100%, 100% and 63%, respectively (P = 0.004).
  
  
  CONCLUSIONS
  DLBCL patients with negative and mild metabolism PET/CT following first-line treatment had good prognosis, who needed no additional therapy. While patients with positive PET/CT had poor prognosis, those patients should receive biopsy before adjusting treatment regimen because of the high false-positive rate.
authors: Peking University Cancer Hospital & Institute, Beijing, China.
authors: Zhi-tao
authors: ZT
authors: Ying
authors: Xue-juan
authors: XJ
authors: Wang
authors: Yu-qin
authors: YQ
authors: Song
authors: Wen
authors: W
authors: Zheng
authors: Xiao-pei
authors: XP
authors: Wang
authors: Yan
authors: Y
authors: Xie
authors: Ning-jing
authors: NJ
authors: Lin
authors: Mei-feng
authors: MF
authors: Tu
authors: Ling-yan
authors: LY
authors: Ping
authors: Wei-ping
authors: WP
authors: Liu
authors: Li-juan
authors: LJ
authors: Deng
authors: Chen
authors: C
authors: Zhang
authors: Zhi
authors: Z
authors: Yang
authors: Jun
authors: J
authors: Zhu
mesh_terms: D000368:Aged; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D019788:Fluorodeoxyglucose F18